Trial reportInternational journal of methods in psychiatric research2020
Theranostic markers for personalized therapy of spider phobia: Methods of a bicentric external cross-validation machine learning approach.
Trial report in International journal of methods in psychiatric research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03208400 (Exposure Treatment in Anxiety Disorders), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exposure Treatment in Anxiety Disorders: Proof of Principle for an a Priori Response Prediction Approach
Who cites it
8 citing papers in PubMed, 37 citations in OpenAlex.
- Theranostic markers for personalized therapy of spider phobia: Methods of a bicentric external cross-validation machine learning approach.International journal of methods in psychiatric research · 2020Trial
- Association of Daily Step Count With Depressive Symptoms in Patients With Major Depressive Disorder Using a Smartphone App (ReMAP): Longitudinal Study.JMIR mental health · 2026Article
- Resting-state functional connectivity in anxiety disorders: a multicenter fMRI study.Molecular psychiatry · 2025Article
- Impact of NPSR1 gene variation on the neural correlates of phasic and sustained fear in spider phobia-an imaging genetics and independent replication approach.Social cognitive and affective neuroscience · 2024Article
- Enhancing biofeedback-driven self-guided virtual reality exposure therapy through arousal detection from multimodal data using machine learning.Brain informatics · 2023Article
- Inhibitory control and its modification in spider phobia - Study protocol for an antisaccade training trial.PloS one · 2023Article
- Individual-Level Prediction of Exposure Therapy Outcome Using Structural and Functional MRI Data in Spider Phobia: A Machine-Learning Study.Depression and anxiety · 2023Article
- ENIGMA-anxiety working group: Rationale for and organization of large-scale neuroimaging studies of anxiety disorders.Human brain mapping · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEmbedded in the Collaborative Research Center "Fear, Anxiety, Anxiety Disorders" (CRC-TRR58), this bicentric clinical study aims at identifying biobehavioral markers of treatment (non-)response by applying machine learning methodology with an external cross-validation protocol. We hypothesize that a priori prediction of treatment (non-)response is possible in a second, independent sample based on multimodal markers.
methodsOne-session virtual reality exposure treatment (VRET) with patients with spider phobia was conducted on two sites. Clinical, neuroimaging, and genetic data were assessed at baseline, post-treatment and after 6 months. The primary and secondary outcomes defining treatment response are as follows: 30% reduction regarding the individual score in the Spider Phobia Questionnaire and 50% reduction regarding the individual distance in the behavioral avoidance test.
resultsN = 204 patients have been included (n = 100 in Würzburg, n = 104 in Münster). Sample characteristics for both sites are comparable. DISCUSSION: This study will offer cross-validated theranostic markers for predicting the individual success of exposure-based therapy. Findings will support clinical decision-making on personalized therapy, bridge the gap between basic and clinical research, and bring stratified therapy into reach. The study is registered at ClinicalTrials.gov (ID: NCT03208400).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.